ArticleJournal of central nervous system disease2022

The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.

Rehana Z Hussain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.